We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Advanz

News List

CMA fines Advanz over ‘excessive and unfair’ pricing of thyroid drug pharmatimes
August 06, 2021
The Competition and Markets Authority (CMA) in the UK has found that pharma company Advanz charged ‘excessive and unfair’ prices for supplying liothyronine tablets, a common medication used to treat thyroid hormone deficiency.
Over £100mn in fines for pharma firms hiking prices of crucial thyroid drug europeanpharmaceuticalreview
July 30, 2021
The Competition and Markets Authority fines Advanz and two others for hiking prices of liothyronine tablets by 1,110 percent in eight years.
Nordic Capital acquires Advanz Pharma for $846m pharmaceutical-technology
June 03, 2021
Nordic Capital subsidiary Cidron Aida Bidco has acquired all issued and to-be-issued limited voting share capital of UK-based speciality pharmaceutical company, Advanz Pharma, for a total value of nearly $846m.
Nordic Capital makes a bid to purchase Advanz Pharma in $846 mn deal expresspharma
January 28, 2021
Under the offer, shareholders would receive a price of $17.26 per Advanz Pharma share.